Mr Mrs Miss Ms Dr Other

Dr
Amy
Dawson

Patent Attorney

Glasgow Office

Life sciences

Telephone. +44(0) 141 229 5800
Email. [email protected]
Vcard
Linkedin

Experience

Amy joined HGF Glasgow in May 2020 as part of the Life Sciences group.

She graduated from the University of Glasgow with a first-class MSci in Immunology with Work Placement. This included a 12-month placement at GlaxoSmithKline R&D. Amy completed a PhD in Cancer Studies from the University of Glasgow. Her research involved using single cell RNA sequencing technology and proteomics to investigate the interaction of leukaemic stem cells and immune cells in the cancer microenvironment. Amy has also completed a post graduate certificate in Intellectual Property from Bournemouth University.

Since joining HGF, she has experience with client management, IP landscaping, drafting and prosecution, including UK and European prosecution. In most recent years, Amy has experience in the cell and gene therapy field, with particular experience in programmable gene therapy technologies and synthetic promoters.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

MSCI

MSci in Immunology

PHD

PhD in Cancer Sciences

POSTGRADUATE DIPLOMA OR CERTIFICATE

Postgraduate Certificate Intellectual Property

Publications

NK Cell Therapy – an IP update

View publication online

New Practice at the EPO: Divisional Applications and Sequence Listings

View publication online

The EPO ‘How To’ guide for antibody applications in Europe

View publication online

CSR

Amy is a member of the IP Inclusive Scotland Committee.

Related News

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Post Sale Confusion – dupes and lookalikes beware?

Last month, the UK Supreme Court issued its highly-anticipated decision in Iconix Luxembourg Holdings SARL v Dream Pairs Europe Inc and another [2025] UKSC 25. Helpful background to the dispute …

Read article

A leading case - beware sequence errors in patent claims

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc [2025] EWHC 1240 (Pat) – Mr Justice Meade – 20 May 2025 The UK Patents Court has held that Samsung Bioepis’ and Amgen’s …

Read article

ICELAND left out in the cold by the General Court

Earlier in the month, the EU General Court issued its decision on Iceland Foods Ltd’s appeal of a decision of the Grand Board of Appeal of EUIPO to invalidate an …

Read article

HGF recognised in Managing IP’s New “Trusted Talent” Table in Germany

We are proud to announce that HGF has been ranked in Managing IP’s newly launched Trusted Talent table in Germany, a recognition of our ongoing commitment to excellence in intellectual …

Read article

Briefing Note: UKIPO SEP Consultation

Overview and Strategic Context The UKIPO’s 2025 consultation on Standard Essential Patents (SEPs), announced on 15 July 2025, signals a potential policy shift in how the UK approaches SEP licensing …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us